Dermatitis and Aging-Related Barrier Dysfunction in Transgenic Mice Overexpressing an Epidermal-Targeted Claudin 6 Tail Deletion Mutant

Tammy-Claire Troy1, Azadeh Arabzadeh1,2, Nathalie M.K. Larivièrè1,2, Abebola Enikanolaiye1,2, Kursad Turksen1,2,3,4*

1 Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 2 Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada, 3 Divisions of Dermatology and Endocrinology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada, 4 Division of Reproductive Endocrinology, Department of Obstetrics, Gynaecology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Abstract

The barrier function of the skin protects the mammalian body against infection, dehydration, UV irradiation and temperature fluctuation. Barrier function is reduced with the skin’s intrinsic aging process, however the molecular mechanisms involved are unknown. We previously demonstrated that Claudin (Cldn)-containing tight junctions (TJs) are essential in the development of the epidermis and that transgenic mice overexpressing Cldn6 in the suprabasal layers of the epidermis undergo a perturbed terminal differentiation program characterized in part by reduced barrier function. To dissect further the mechanisms by which Cldn6 acts during epithelial differentiation, we overexpressed a Cldn6 cytoplasmic tail deletion mutant in the suprabasal compartment of the transgenic mouse epidermis. Although there were no gross phenotypic abnormalities at birth, subtle epidermal anomalies were present that disappeared by one month of age, indicative of a robust injury response. However, with aging, epidermal changes with eventual chronic dermatitis appeared with a concomitant barrier dysfunction manifested in increased trans-epidermal water loss. Immunohistochemical analysis revealed aberrant suprabasal Cldn localization with marked down-regulation of Cldn1. Both the proliferative and terminal differentiation compartments were perturbed as evidenced by mislocalization of multiple epidermal markers. These results suggest that the normally robust injury response mechanism of the epidermis is lost in the aging Invulc-r-Cldn6-CΔ196 transgenic epidermis, and provide a model for evaluation of aging-related skin changes.

Introduction

Formed during development by a series of cell commitment, mesenchymal-epithelial cell interactions, and terminal differentiation, the mammalian epidermis undergoes continuous self-renewal in a tightly regulated process of epidermal cell proliferation and differentiation [1–3]. As the end result of terminal differentiation, the robust barrier function of the skin protects against microorganism invasion and UV irradiation, inhibits water loss, regulates body temperature and is an important part of the host defense system [4]. These important functions decline in efficiency with aging, leading to an inefficient epidermal injury response and dermatitis [5–7], for reasons that are not yet understood.

Tight junctions (TJs) are essential not only for dividing epidermal cells into apical and basolateral compartments to create cell polarity [8], but also for the existence of skin barrier function by regulating the selective permeability of the paracellular pathway [9–11]. The selectivity function of TJs is imparted by Claudins (Cldns), a family of 23 highly conserved tetraspan membrane proteins whose heterogeneity stems in large part from distinctly charged amino acid sequences in the first external loop [11–13]. Cldn type and mixing ratio thus provide for the specific permeability requirements of different epithelia [12]. The importance of Cldns in epidermal differentiation and barrier function has been confirmed by experiments in which Cldn expression has been perturbed in epidermal cells; for example, Cldn1 knockout mice die shortly after birth due to skin barrier dysfunction [14]. Invulc-r-Cldn6 (Inv-Cldn6) transgenic mice also suffer skin barrier dysfunction, the severity/lethality of which is dependent upon the level of Cldn6 overexpression [15,16]. Further, Inv-Cldn6-CΔ196 transgenic mice overexpressing a cytoplasmic tail-абlated Cldn6 display epidermal hyperproliferation, apparently due to an inefficiency of Cldn protein membrane targeting, as a result of the unfolded protein response pathway [17].

The latter data suggest the importance of the cytoplasmic tail portion of Cldn molecules in cell signaling during epidermal differentiation. The cytoplasmic tail of different Cldns, while relatively constant in length, is divergent in sequence, but a number of putative functional protein domains are present in many family members [12,18]. To address the activities of the functional domains in more detail, we again used the involucrin promoter (Inv) this time to target a shorter deletion in the...
cytoplasmic tail (Cldn6-CA196) to the differentiative compartment of the epidermis. The Inv-Cldn6-CA196 transgenic mice possess subtle epidermal differentiation abnormalities at birth that by 1-month of age are completely normalized. However, with aging, Inv-Cldn6-CA196 mice suffered dermatitis, often manifested as patent wounds in repetitive grooming areas. Normal hydration levels were not maintained in the aging skin, and immunohistochemistry revealed perturbations in the expression and localization of multiple Cldns, as well as various classical markers of epidermal differentiation. These results suggest that the normally robust injury response mechanism of the epidermis is lost in the aging Inv-Cldn6-CA196 transgenic epidermis and provides a model for evaluation of chronic dermatitis and aging-related skin changes.

Methods

Generation of Inv-Cldn6-CA196 transgenic mice

The Inv-Cldn6-CA196 construct [19] was injected into ova collected from superovulated CD1 mice to generate viable lines at the Ottawa Hospital Research Institute (OHRI) Transgenic Mouse Facility as previously described [20]. Genotyping was performed by PCR using genomic DNA and primers specific for Cldn6 (5'-ATG GCC TCT ACT GTG GTG CA-3') and the FLAG® tag (5'-TCA CTT GTC ATC GTC GTC CTT G-3'). Age-matched wild type and Inv-Cldn6-CA196 transgenic mice were photographed using a Nikon COOLPIX950 digital camera (Nikon) for image processing with Adobe Photoshop version 7.0 (Adobe Systems). All research complied with the principles and guidelines of the Canadian Council on Animal Care and was approved by the Ottawa Hospital Research Institute Animal Care Committee. Once the dermatitis phenotype became unmanageable, Inv-Cldn6-CA196 transgenic mice were euthanized according to institutional and legislative policies.

Sample preparation, histology and immunohistochemistry

a) Sample collection. Freshly dissected skin samples (~1 cm²) were collected at various postnatal time points (birth, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 5 months, 6 months) from either the mid-dorsal region or areas of frequent grooming (e.g. the neck and behind the ears) of Inv-Cldn6-CA196 transgenic mice and their age-matched CD1 counterparts.

b) Frozen sections. Frozen sections were required for immunolocalization with FLAG® antibodies, whereas histology and all other immunostaining procedures were performed using paraffin-embedded sections. For frozen sections, skin samples were embedded in HistoPrep (Fisher Scientific), solidified using dry ice-chilled isopentane and 5% ethanol washes to water. Following antigen unmasking and dewaxed using toluene and rehydrated in a reverse graded series of ethanol washes (0.8% BSA, 1% gelatin in PBS), skin samples were incubated for 1 hour in antibodies appropriately diluted in incubation buffer (1% goat serum, 0.8% BSA, 1% gelatin in PBS) [15]. Antibodies recognizing the following proteins were used: FLAG® (M2 monoclonal) (1:40; Sigma), K15 (1:100; rabbit #UC55), K5 (1:100; rabbit #3054); K14 (1:100; rabbit #199), K1 (1:100; rabbit #UC81), K6 (1:200; BabCO), K17 (1:500; a gift from Dr. Pierre Coulombe, Johns Hopkins), involucrin (1:100; BabCO), filaggrin (1:100; BabCO), loricrin (1:100; rabbit #UC34), Cldn1 (6:100; Zymed Laboratories), Cldn2 (1:200; Zymed Laboratories), Cldn3 (1:50; Zymed Laboratories), Cldn5 (1:100; Zymed Laboratories), Cldn6 (1:100; hen #3677), Cldn11 (1:100; hen #3680), Cldn12 (1:100; hen #5186) and Cldn18 (1:100; rabbit #A9953). Following washes (0.8% BSA, 1% gelatin in PBS), skin samples were incubated for 1 hour at room temperature with FITC-conjugated secondary antibodies against mouse, rabbit and chicken (1:50; Jackson ImmunoResearch) diluted in incubation buffer. After washes in wash buffer and PBS, sections were mounted with Moviol 4-88 (Calbiochem) containing 2.5% 1,4 diazobicyclo-[2,2,2]-octane (DABCO; Sigma) for observation on a Zeiss Axioplan 2 fluorescence microscope equipped with an AxioCam camera and Axio Vision 2.05 software (Carl Zeiss); digital images were processed using Adobe Photoshop version 7.0 (Adobe Systems).

Protein isolation and immunoblotting

Skin samples (0.4 g) were dissected from either the mid-dorsal region or areas of frequent grooming (e.g. the neck and behind the ears) of Inv-Cldn6-CA196 transgenic mice and their age-matched CD1 counterparts and whole cell protein extracts were prepared by homogenizing in SDS extraction buffer (62.5 mM Tris pH 6.8, 25% glycerol, 2% SDS and 2% β-mercaptoethanol with peptatin A and a complete mini protease inhibitor cocktail tablet [Roche]) followed by centrifugation. Following a 30-minute incubation in sample reducing buffer (62.5 mM Tris pH 6.8, 25% glycerol, 2% SDS, 0.1% bromophenol blue and 2% β-mercaptoethanol), boiling and centrifugation, 10 μg of soluble proteins were separated on 12% SDS-polyacrylamide gels and transferred to nitrocellulose [17]. After blocking for non-specific antibody binding (5% skim milk, TBS/0.1% tween-20 [TBS-T]), blots were incubated at 4°C overnight with diluted (5% skim milk, TBS-T) antibodies against FLAG® (polyclonal) (1:500; Sigma) and GAPDH (1:20,000; Abcam). After several washes in TBS-T, blots were incubated in diluted (5% skim milk, TBS-T) HRP-conjugated antibodies against mouse and rabbit IgG (1:20,000; Amersham) for 1 hour at room temperature and washed with TBS-T before incubation with chemiluminescent HRP substrate (Millipore) and visualization on BioMax XAR autoradiography film (Kodak). Films were scanned and digital images were prepared using Adobe Photoshop version 7.0 (Adobe Systems).

Barrier integrity assay

Trans-epidermal water loss (e.g. impedance) of both Inv-Cldn6-CA196 transgenic and wild type mouse skin was measured using a dermal phase meter (DPM) (Nova Technology Corporation) as described [16]. Diminished barrier integrity is reflected in higher DPM values over time as depicted digitally with EDWINA software (Nova Technology Corporation) and converted into graphical form with Excel software (Microsoft).

Cornified envelope extracts

Using dorsal skin samples of CD1 and Inv-Cldn6-CA196 transgenic mice, purified cornified envelope extracts were prepared as described [16,21,22]. Briefly, skin samples were
immersed in hot extraction buffer (0.1 M Tris-HCl pH 8.5, 2% SDS, 20 mM dithiothreitol, 5 mM EDTA), followed by 15-minute incubation at 95°C and gentle centrifugation before observation using an Olympus CK2 inverted microscope (Olympus) equipped with a Nikon COOLPIX 4500 digital camera (Nikon). Images were produced with Adobe Photoshop version 7.0 (Adobe Systems).

Results

Generation and expression analysis of Inv-Cldn6-CΔ196 transgenic mice

We previously reported that overexpression of a Cldn6 lacking the C-terminal half of the cytoplasmic tail domain (e.g. truncation after amino acid 196; Cldn6-CΔ196) (Figure 1A-C) in the suprabasal compartment of the mouse epidermis results in marked hyperproliferative squamous invaginations/cysts replacing hair follicles and lethal epidermal barrier dysfunction [19]. The rationale for generating the Δ196 mutation was based on two main factors. First, we already knew that tailless Cldn6 was not targeting to the membrane appropriately. Second, we wanted to delete the PDZ domain that is at the tip of the cytoplasmic tail as well as putative phosphorylation sites, which could be accomplished by deletion from amino acid 196. The choice of 196 rather than 195 or 197, both of which would also have accomplished removal of the PDZ and putative phosphorylation sites, was one of convenience for the steps required to make our mutant insert. Because we have demonstrated previously that the level of Cldn6 overexpression correlates to the severity of the phenotype [15,16], we re-derived F0s with lower Cldn6-CΔ196 expression to avoid lethality and explore the function of the Cldn6 tail in postnatal animals; levels of expression of the mutant Cldn6 is half of that observed in our previously generated mice. Nine Inv-Cldn6-CΔ196 positive F0 transgenic mice (five females and four males) were generated and three viable lines exhibiting indistinguishable phenotypes were successfully established. Cldn6-CΔ196 expression was confirmed to be confined to the upper spinous and granular layers of the epidermis and localized to cell membranes, mimicking endogenous Cldn6 expression (Figure 1D). Immunoblotting confirmed a ~19.5kDa band corresponding to the transgene product in skin samples from transgenic (TG) but not wild type (WT) skin samples using anti-GAPDH as a loading control (E). Trans-epidermal water loss measurements confirmed no skin barrier dysfunction in the Inv-Cldn6-CΔ196 transgenic mice at birth (F). This was further supported by evaluation of cornified envelopes; which were characterized by a rigid shape and uniform size comparable to that of the wild type (G). Inv-Cldn6-CΔ196 mice were easily identifiable by their frizzed and lacklustre coat appearance as compared to the wild type, a phenotype that persisted throughout life (H). doi:10.1371/journal.pone.0007814.g001

Figure 1. Inv-Cldn6-CΔ196 transgenic mice. The Cldn6 protein sequence is shown; transmembrane-spanning regions are encased within boxes, the CXXC motifs are underlined, and the truncation site is indicated with an arrow (A). The Inv-Cldn6-CΔ196 mutant was created by deleting the C-terminal half of the cytoplasmic tail domain of Cldn6 after amino acid 196 (B). The Inv promoter was use to drive transgene expression to the suprabasal compartment of the transgenic mouse epidermis, where TJs are localized (C). Transgene expression was confirmed to be restricted to the upper spinous and granular layers of the epidermis as visualized by immunohistochemistry using anti-FLAG antibodies (D) and immunoblotting confirmed a ~19.5kDa band corresponding to the transgene product in skin samples from transgenic (TG) but not wild type (WT) skin samples using anti-GAPDH as a loading control (E). Trans-epidermal water loss measurements confirmed no skin barrier dysfunction in the Inv-Cldn6-CΔ196 transgenic mice at birth (F). This was further supported by evaluation of cornified envelopes; which were characterized by a rigid shape and uniform size comparable to that of the wild type (G). Inv-Cldn6-CΔ196 mice were easily identifiable by their frizzed and lacklustre coat appearance as compared to the wild type, a phenotype that persisted throughout life (H).
Epidermal maturation is delayed in Inv-Cldn6-CA196 mice

Although in the epidermis there were no gross phenotypic abnormalities or barrier dysfunction apparent at birth, histological examination revealed that the newborn (Figure 2A) and 1-week-old (not shown) transgenic epidermis was moderately thicker than that of the wild type, with a thicker stratum corneum, a less-compacted granular layer and an overall expanded suprabasal compartment. By 2-weeks of age, the Inv-Cldn6-CA196 epidermis displayed a more compact and organized granular layer, but it remained less mature and thicker than that in the wild type animals (Figure 2B). Typical epidermal thinning had commenced in the transgenic epidermis by 3-weeks of age (~1 week later than wild type; not shown) and by 1-month of age the Inv-Cldn6-CA196 transgenic epidermis was histologically indistinguishable from that of the wild type (Figure 2C).

Consistent with the histological results, abnormalities in the expression of epidermal differentiation markers were present in neonatal Inv-Cldn6-CA196 mice but these also normalized by 1-month of age (Figure 3; the transgenic and wild type epidermis after 2 weeks and 1 month are shown). For example, K5 and K15 were restricted to basal cells at all time points in both the wild type and Inv-Cldn6-CA196 epidermis (not shown), but K14, another basal compartment marker, occupied an expanded zone extending into the suprabasal compartment at birth and until epidermal thinning was achieved in the Inv-Cldn6-CA196 epidermis (Figure 3A). The suprabasal layers of the epidermis normally express K1 [24], and when in a state of hyperploration, K6 and K17 [25–27]. While neither K6 nor K17 was expressed throughout the time analyzed (not shown), a broadened compartment of K1-positive cells, consistent with the increased number of suprabasal cell layers observed histologically, was seen early but normalized by 1-month of age in the Inv-Cldn6-CA196 transgenic epidermis (Figure 3B). Similarly the expression compartments of various structural proteins in the stratum corneum, including involucrin (Figure 3C), filaggrin and loricrin (not shown), were also expanded in the juvenile Inv-Cldn6-CA196 epidermis, and a tightly compacted stratum corneum was not observed in the transgenic epidermis until thinning comparable to that in the wild type was achieved.

In parallel with changes in epidermal markers, the thickened newborn and 1-week-old Inv-Cldn6-CA196 epidermal basal layer was devoid of Cldn1, which was clearly present in the wild type epidermis (not shown). However, after 2 weeks, sporadic Cldn1-positive basal cells were evident, and the frequency increased as thinning progressed until 1-month of age when Cldn1-positive cells completely occupied the basal and suprabasal compartments in both the transgenic and wild type mice (Figure 3D). The suprabasal-specific Cldns, Cldn6 (Figure 3E), Cldn11, Cldn12 and Cldn18 (not shown) were seen in the expanded suprabasal region of the Inv-Cldn6-CA196 epidermis; each Cldn evaluated maintained a strictly membranous localization and normalized by 1-month to a zone comparable to wild type. Cldns that are not normally expressed in the epidermis (e.g. Cldn2, Cldn3 and Cldn5) [16] were not observed in either the wild type or Inv-Cldn6-CA196 epidermis at any time evaluated (not shown). The data suggest that Inv-Cldn6-CA196 transgenic mice are born with differentiation abnormalities leading to slower epidermal maturation, but these are too mild to manifest in skin barrier defects or death, and are repaired between birth and 1-month of age.

Inv-Cldn6-CA196 mice experience age-related perturbations in epidermal differentiation and injury repair resulting in chronic dermatitis

Although by 1-month of age the Inv-Cldn6-CA196 epidermis was morphologically and biochemically indistinguishable from the
wild type (Figure 2 and Figure 3), as early as 2-months (not shown) of age, the transgenic epidermis showed histological evidence of thickening that persisted, and was somewhat exacerbated, at 3 (Figure 4A) and 6 (Figure 4B) months. At the latter ages, an expanded stratum corneum, increased number of suprabasal/spinous cell layers and a less compacted granular layer were clearly present, and reminiscent of the 2-week-old Inv-Cldn6-CΔ196 epidermis (see above).

The histological results suggested that intrinsic changes occurred in the transgenic epidermis, a possibility supported by the perturbed expression of differentiation markers; because results were similar from 2- to 6-months of age, we report results from 3-month-old Inv-Cldn6-CΔ196 transgenic mice only (Figure 5). K14 was expressed throughout the basal and suprabasal compartments in the aging Inv-Cldn6-CΔ196 epidermis (Figure 5A), while K5 (not shown) and K15 (Figure 5B) remained restricted to basal cells as in the wild type epidermis. K1 (Figure 5C) was seen throughout an expanded suprabasal zone in the transgenic epidermis corresponding to the increased number of spinous cell layers; however, neither K6- (Figure 5D) nor K17-positive (Figure 5E) interfollicular epidermal cells were observed nor was there any up-regulation in the expression of Ki67 or CD3 (not shown), suggesting no detectable hyperproliferation or immune cell infiltration. The localization of involucrin (Figure 5F), loricrin (not shown) and filaggrin (Figure 5G) suggested that there were also perturbations in terminal differentiation in the aged Inv-Cldn6-CΔ196 epidermis, with each marker occupying an expanded zone of expression consistent with the abnormal morphological appearance of the stratum corneum described above.

Cldn expression was also modified with striking anomalies consistent with those we reported earlier in an acute irritant [12-O-tetradecanoylphorbol-13-acetate (TPA)]-induced epidermal injury response [25]. The number of Cldn1-positive basal and suprabasal

Figure 3. Perturbation of markers of epidermal differentiation. Immunofluorescence was used to evaluate various markers of epidermal differentiation including K14 (A), K1 (B), involucrin (C), Clodn1 (D) and Clodn6 (E) in Inv-Cldn6-CΔ196 mice as compared to their age-matched wild type counterparts. In each case abnormalities were present in samples from 2-week old (left panel) transgenic mice that were normalized by 1-month of age (right panel). For example, the K14 expression zone was extended into the suprabasal compartment the Inv-Cldn6-CΔ196 epidermis until epidermal thinning was achieved. In addition, broadened K1 and involucrin expression compartments was seen early but normalized by 1-month of age. Sporadic Clodn1-positive basal cells were evident in the 2-week old transgenic epidermis; by 1-month of age Clodn1-positive cells occupied both the basal and suprabasal compartments reminiscent of the wild type. Clodn6, a suprabasal-specific Clodn, was observed in an expanded zone early on, and was normalized by 1-month of age.

doi:10.1371/journal.pone.0007814.g003
cells was reduced (Figure 6A) and an expanded suprabasal zone of Cldn6- (Figure 6B), Cldn11- (Figure 6C), Cldn12- (Figure 6D) and Cldn18-positive cells (Figure 6E) was seen in the transgenic epidermis; concomitantly, a shift away from a strictly membrane localization was evident. Cldn2, Cldn3 and Cldn5 were not expressed in either wild type or transgenic animals (not shown).

Taken together, the data suggest an intrinsic propensity for injury and inefficient repair that increases with aging in the Inv-Cldn6-CΔ196 epidermis. This is further supported by two lines of evidence. First, histological and biochemical changes resulting from TPA treatment were seen earlier (4 hours versus 12 hours) and repaired more slowly (no repair versus normalization by 96 hours) in Inv-Cldn6-CΔ196 versus wild type epidermis when mice were tested at 1 month of age (data not shown). Second, obvious signs of dermatitis, especially in areas subjected to repetitive mechanical stress during grooming (e.g., the neck and behind the ears), were seen in the aging Inv-Cldn6-CΔ196 epidermis (Figure 7A). Histological evaluation of skin samples from these regions revealed a significantly thickened epidermis with an increased number of spinous/suprabasal cell layers and cellular disorganization; the upper differentiation layers were also abnormal, with parakeratosis, the prevalent appearance of nuclei, an improperly packed granular layer and a thicker stratum corneum (Figure 7B). In the dermatitis-affected areas, K14 (Figure 5H) and K5 (not shown) were expressed in an expanded zone far into the suprabasal compartment, and K15 expression was only sporadically expressed (Figure 5I). K1 was localized throughout the thickened suprabasal zone of the dermatitis-affected Inv-Cldn6-CΔ196 epidermis, and staining appeared punctate, suggesting a keratin filament bundling defect (Figure 5J). K6 was seen consistently throughout the basal and suprabasal layers of the dermatitis-affected epidermis (Figure 5K); K17-positive basal and suprabasal cells were somewhat more sporadically seen (Figure 5L). Expression compartments for involucrin (Figure 5M), loricin (not shown) and filaggrin (Figure 5N) were also expanded, with an obvious packing defect reminiscent of the observed histological abnormalities of the

![Figure 4](https://example.com/figure4.png) **Figure 4.** Histological evidence of epidermal abnormalities in the aging Inv-Cldn6-CΔ196 transgenic epidermis. Histological evidence of epidermal abnormalities emerged in aging Inv-Cldn6-CΔ196 transgenic mice after 3 (A) and 6 (B) months as compared to the wild type. These included an expanded stratum corneum, as well as an expanded suprabasal zone and a less compacted granular layer suggesting an intrinsic propensity for injury and inefficient repair that increases with aging in the Inv-Cldn6-CΔ196 epidermis. doi:10.1371/journal.pone.0007814.g004

![Figure 5](https://example.com/figure5.png) **Figure 5.** Aberrance in markers of epidermal differentiation during aging. Changes in the epidermal differentiation program of the aging Inv-Cldn6-CΔ196 transgenic epidermis were evaluated by immunofluorescence and compared to their age-matched wild type counterparts (samples from 3-month-old mice are shown – left panel); their expression/localization in dermatitis-affected areas is also indicated (right panel). K14 was expressed throughout the basal and suprabasal compartments in the aging Inv-Cldn6-CΔ196 epidermis (A), while K15 remained restricted to basal cells (B). The zone of K1 expression was expanded in the 3-month-old transgenic epidermis (C); however, neither K6- (D) nor K17-positive (E) cells were observed. An expanded zone of expression, and improper packing, of involucrin (F) and filaggrin (G) suggested perturbations in terminal differentiation program of the aged Inv-Cldn6-CΔ196 epidermis. In the dermatitis-affected areas, K14 (H) expression was expanded far into the suprabasal compartment, while K15 was only sporadically observed (I). A punctate K1 localization was evident throughout the thickened suprabasal zone of the dermatitis-affected Inv-Cldn6-CΔ196 epidermis (J), and K6- (K) and K17-positive (L) basal and suprabasal cells were observed. In addition, involucrin (M) and filaggrin (N) expression compartments were also expanded, with obvious packing defects evident. doi:10.1371/journal.pone.0007814.g005
Figure 6. Evaluation of Cldns in the aging Inv-Cldn6-CΔ196 transgenic epidermis. The expression/localization of Cldns was also perturbed in the aging Inv-Cldn6-CΔ196 transgenic epidermis (samples are from 3-month-old mice – left panel); the dermatitis-affected zones are also shown (right panel). Cldn1-positive basal and suprabasal cells were reduced in the aging Inv-Cldn6-CΔ196 epidermis (A). In addition, a shift away from a strictly membrane localization and an expanded zone of suprabasal Cldns was evident - Cldn6 (B), Cldn11 (C), Cldn12 (D) and Cldn18 (E). These abnormalities were strikingly exacerbated in the dermatitis-affected epidermis. For instance, the basal and lower suprabasal layers were void of Cldn1 localization (F). In addition, Cldn6 (G), Cldn11 (H), Cldn12 (I) and Cldn18 (J) localization was observed throughout the expanded suprabasal zone with membranous localization less evident in the lower suprabasal layers.

doi:10.1371/journal.pone.0007814.g006
Discussion

In this study, we used transgenic mouse technology to expand on our structure-function approach to elucidating the role of the cytoplasmic tail of Cldn6 in epidermal development and the formation and maintenance of skin barrier integrity. We demonstrate that Inv-Cldn6-CΔ196 mice display epidermal differentiation abnormalities at birth that result in slower epidermal maturation but are apparently normalized by 1-month of age. However, with aging, intrinsic properties of the Inv-Cldn6-CΔ196 epidermis are manifested by a propensity for injury and inefficient repair, eventually resulting in chronic dermatitis especially in areas subjected to frequent insult via grooming. Changes in Cldn expression and localization suggest marked changes in the presence and function of TJ's, as also evidenced by skin barrier dysfunction. Taken together, our data suggest that the overexpression of a Cldn tail truncation mutant in the suprabasal compartment of the mouse epidermis results in its delayed maturation, a propensity for injury, diminished repair and skin barrier deficiency reminiscent of the intrinsic aging process of human skin.

It is well established that the formation of the epidermal permeability barrier (EPB) is developmentally regulated [16,28–30] and that disruption or delay in its formation before birth has a critical role in the survival of the organism [31–34]. Previously we reported that a perturbation of Cldn6 expression levels at its endogenous site of expression - the suprabasal layer of the epidermis - alters epidermal development and the formation of the EPB [15,16]. However, depending on whether normal or mutant forms of Cldn6 are expressed and at what levels, the severity of phenotypic anomalies varies markedly [15–17,19]. For example, perinatal lethality resulting from a severely compromised epidermal differentiation program and dysfunctional EPB results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) results in a lethal barrier dysfunction with marked hyperproliferative squamous invagination and a propensity for injury and diminished repair. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15]. In contrast, apparently normal prenatal epidermal development and formation of a functioning EPB, but an abnormal postnatal lifelong keratinocyte hyperproliferation leading to progressive thickening of the epidermis - but no dermatisis, results when a mutant form of Cldn6 lacking its entire tail domain (Inv-Cldn6-CΔ196) is expressed at high levels [16]; while with lower levels of expression, less severe defects occur with the capacity for normalization of EPB function [15].

The morphological and biochemical abnormalities described predict altered permeability barrier properties and potentially barrier dysfunction in areas of repeated insult of the aged Inv-Cldn6-CΔ196 transgenic epidermis. In keeping with this hypothesis, TEWL measurements across the dermatitis-affected transgenic skin confirmed an approximately 8-fold increase in water loss and a barrier deficient phenotype (C).

Figure 7. Aging-associated barrier dysfunction. Upon gross observation, obvious signs of dermatitis were evident in aging Inv-Cldn6-CΔ196 mice, especially in areas subjected to repetitive mechanical stress such as the neck and behind the ears (A). Histological evaluation revealed a significantly thickened epidermis with an increased number of spinous/suprabasal cell layers and cellular disorganization; the upper differentiation layers were also abnormal, with parakeratosis, the prevalent appearance of nuclei, an improperly packed granular layer and a thicker stratum corneum (B). TEWL measurements across the dermatitis-affected transgenic skin confirmed an approximately 8-fold increase in water loss and a barrier deficient phenotype (C). doi:10.1371/journal.pone.0007814.g007

Figure 6J
sequence heterogeneity among Cldn isoforms, and in most cases contains a PDZ-binding motif that enables Cldns to directly interact with the TJ-associated MAGUKs (ZO-1, ZO-2, and ZO-3) as well as with MUPP1 and PATJ [35–38]. For at least some Cldns (e.g., 1 and 5), the cytoplasmic tail upstream of the PDZ-binding motif is thought to be required for targeting to the TJ complex [39] and contributes to protein stability [17,40]. Post-translational modifications within the tail domain, including phosphorylation and palmitoylation, are also thought to regulate Cldn activities, including their targeting to the membrane and insertion into TJs [41], but to date most Cldns have not been subjected to exhaustive analysis. Thus, the similarities and differences between Inv-Cldn6-CΔ187 and Inv-Cldn6-CA196 mice are of interest. Our data suggest that the phenotype observed in the Inv-Cldn6-CΔ187 epidermis reflects protein instability and an unfolding protein response. On the other hand, the delayed maturation and age-related deficit in wound healing and repair in the Inv-Cldn6-CΔ196 epidermis most likely involves an aberrant interaction with the cytoskeleton. Although to date no direct interaction between the cytoplasmic tail of Cldns and cytoskeletal molecules has been shown, the possibility of such direct interactions is not unlikely considering the known role of the actin cytoskeleton, for example, in cell shape and cell polarity [42–44].

Despite the importance of the skin barrier to the survival of the mammalian species, the molecular mechanisms governing its formation and maintenance are not well-understood, nor are the changes that occur during the intrinsic aging process of the skin. In humans, aging-related changes in the skin are widespread and result from both intrinsic (gene mutations, hormonal changes, cellular metabolism) and extrinsic (UV exposure, chemicals, pollutants) factors. While extrinsic factors affect mainly the dermis, the epidermis is the main target of intrinsic skin aging processes where, especially in sun-exposed skin, changes occur often with initial generalized epidermal thickening, indicative of epidermal hyperplasia and reduced capacity to repair, such that the epidermis becomes prone to a number of skin conditions including dermatitis, eczema and ulceration [6,7,43–49]. Only recently has it been appreciated that abnormal skin barrier function might underlie these skin conditions [50], although no analysis of Cldn expression has been reported. The murine epidermis, however, does not normally undergo comparable aging-related changes; in fact, once the mouse epidermis is matured it maintains a homeostatic balance and undergoes morphological and biochemical changes only in response to injury or disease. Thus, it was extremely interesting to note that in spite of the fact that Inv-Cldn6-CΔ196 mice achieve a normal–appearing epidermis by one-month of age (by morphology and biochemical markers), with aging they have a high propensity for epidermal injury and a diminished ability to repair lesions, leading eventually to severe dermatitis with associated changes in skin barrier function. It should be noted that this sensitivity to injury and inefficient repair were seen also in young mice subjected to acute injury by application of the irritant TPA (data not shown).

As already indicated, the precise mechanisms by which expression of low levels of Cldn6-CΔ196 in the suprabasal layers of the epidermis leads to age-related changes appearing to mimic those seen in humans are currently not known, but our observations suggest that changes in Cldn homeostasis leading to changes in the epidermal differentiation program play important roles. In this regard, not only changes elicited directly by changes in Cldn6 signaling but also changes imparted by alterations in the expression of other Cldns, notably Cldn1, must be considered. In the developing epidermis, Cldn1 is first restricted to the stratifying layers and matures to occupy the basal layer upon the completion of barrier formation at E17.5 [19]. However, in response to TPA-induced injury and loss of cell polarity seen in tumorigenesis, Cldn1 expression is downregulated in both the basal layer and immediate suprabasal layers of the epidermis [23,51], alterations seen also with aging of the Inv-Cldn6-CΔ196 epidermis. The drastic changes in TEN1, that we observed in severely affected areas of the Inv-Cldn6-CΔ196 epidermis also appear to mimic those seen in the aging human epidermis subjected to stress or injury [47]. Thus the data reported here suggest that the changes in Cldn expression and localization in mice with low expression of Cldn6-CΔ196 in the epidermis lead to relatively subtle changes in the epidermal differentiation program and permeability in the young animal, but render them prone to injury and diminished repair that are exacerbated especially in areas subjected to repeated mechanical trauma, leading to chronic and increasingly severe dermatitis.

In summary, our data add to the evidence that Cldn6, and in particular the C-terminal half of the Cldn6 tail, contribute to the regulation of epidermal differentiation and skin barrier function throughout life. They also support the utility of the Inv-Cldn6-CΔ196 mouse model for studies aimed at understanding intrinsic changes in the aging epidermis and point towards a need to investigate Cldn expression profiles in the aging human epidermis.

Acknowledgments

This study is dedicated to Dr. G. E. Palade for the discovery of tight junctions, together with Dr. M.G. Farquhar. We remain eternally grateful to our dear friend and colleague, Dr. Jane E. Aubin (University of Toronto), for many invaluable discussions and comments on our manuscript. We would like: the thank Dr. Pierre Coulombe (Johns Hopkins) for his gift of anti-K17 antibodies as well as Mrs. Adriana Gamberotta and Mr. Pierre Bradley of the animal care facility of the OHRI. Zaida J. Ticas (MLT) (University of Ottawa) prepared paraaffin-embedded samples and histological sections for evaluation. KT would like to acknowledge Vittorio Paltrinieri for I Found My Love in Portofino, Giorgio Armani for the pleasure of unstructured tailored lines and Isabella Rossellini for Blue Velvet.

Author Contributions

Conceived and designed the experiments: KT. Performed the experiments: TCT AA NML AE. Analyzed the data: TCT KT. Contributed reagents/materials/analysis tools: TCT. Wrote the paper: TCT KT.

References

1. Fuchs E, Raghavan S (2002) Getting under the skin of epidermal morphogenesis. Nat Rev Genet 3: 199–209.
2. Fuchs E (2007) Scratching the surface of skin development. Nature 445: 334–342.
3. Turkien K, Troy TC (1998) Epidermal cell lineage. Biochem Cell Biol 76: 889–898.
4. Pouillof A, Dayan N, Polla AS, Polla LL, Polla BS (2008) The stratum corneum: a double paradox. J Cosmet Dermatol 7: 143–148.
5. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M (2008) Aging Related Skin Phenotype. PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7814
11. Chiba H, Osanai M, Murata M, Koijima T, Sawada N (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778: 588–600.
12. Turksen K, Troy TC (2004) Barriers built on claudins. J Cell Sci 117: 2435–2447.
13. Kato M (2003) CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. Int J Mol Med 11: 683–689.
14. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, et al. (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156: 1099–1111.
15. Troy TC, Rahbar A, Arabzadeh A, Cheung RM, Turksen K (2005) Delayed epidermal permeability barrier formation and hair follicle aberrations in Inv-Cldn6 mice. Mech Dev 122: 805–819.
16. Turksen K, Troy TC (2002) Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development 129: 1775–1784.
17. Arabzadeh A, Troy TC, Turksen K (2006) Role of the cldn6 cytoplasmic tail domain in membrane targeting and epidermal differentiation in vivo. Mol Cell Biol 26: 5876–5887.
18. Gonzalez-Mariscal I, Betanzos A, Nava P, Jaramillo BE (2003) Tight junction proteins. Prog Biophys Mol Biol 81: 1–44.
19. Troy TC, Turksen K (2007) The targeted overexpression of a Claudin mutant in the epidermis of transgenic mice elicits striking epidermal and hair follicle abnormalities. Mol Biotechnol 36: 166–174.
20. Troy TC, Li Y, O’Malley L, Turksen K (2007) The temporal and spatial expression of Claudins in epidermal development and the accelerated program of epidermal differentiation in K14-CaSR transgenic mice. Gene Expr Patterns 7: 425–430.
21. Hohd M, Mehrel T, Lichti U, Turner ML, Roop DR, et al. (1991) Characterization of human keratinin. Structure and function of a new class of epidermal cell envelope proteins. J Biol Chem 266: 6626–6636.
22. Troy TC, Turksen K (2005) Commitment of embryonic stem cells to an epidermal cell fate and differentiation in vitro. Dev Dyn 232: 293–300.
23. Arabzadeh A, Troy TC, Turksen K (2008) Claudin expression modulations reflect an injury response in the murine epidermis. J Invest Dermatol 129: 237–240.
24. Fuchs E, Byrne C (1994) The epidermal rising to the surface. Curr Opin Genet Dev 4: 725–736.
25. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, et al. (1995) Keratins 5, 14, 16, 17 and 19 form heterozygous human keratin complexes. Biochim Biophys Acta 1273: 237–240.
26. McGowan K, Coulombe PA (1999) The wound repair-associated keratins 6, 16, and 17. Insights into the role of intermediate filaments in specifying keratinocyte cytoarchitecture. Subcell Biochem 31: 173–204.
27. McGowan KM, Coulombe PA (1998) Onset of keratin 17 expression coincides with the definition of major epiderhal lineages during skin development. J Cell Biol 143: 469–486.
28. Hardman MJ, Sisi P, Banbury DN, Byrne C (1998) Patterned acquisition of skin barrier function during development. Development 125: 1541–1552.
29. Byrne C, Hardman MJ (2005) Whole-mount assays for gene induction and barrier formation in the developing epidermis. Methods Mol Biol 209: 127–136.
30. Hardman MJ, Moore L, Ferguson MW, Byrne C (1999) Barrier formation in the human fetus is patterned. J Invest Dermatol 113: 1106–1113.
31. Elias PM (2005) Stratum corneum defensive functions: an integrated view. J Invest Dermatol 125: 183–200.
32. Mack JA, Anand S, Maytin EV (2005) Proliferation and cornification during development of the mammalian epidermis. Birth Defects Res C Embryo Today 73: 319–329.
33. Williams ML, Hanley K, Elias PM, Feingold KR (1998) Ontogeny of the epidermal permeability barrier. J Invest Dermatol Symp Proc 3: 75–79.
34. Cartledge P (2000) The epidermal barrier. Semin Neonatol 5: 273–280.
35. Anwer E, Bazellieres E, Palleux-P Richard E, Le Briec A, Massey-Harroche D (2008) Polarity complex proteins. Biochim Biophys Acta 1778: 614–625.
36. Roh MH, Margolis B (2003) Composition and function of PDZ protein complexes during cell polarization. Am J Physiol Renal Physiol 285: F377–387.
37. Heiskala M, Peterson PA, Yang Y (2004) The roles of claudin superfamily proteins in paracellular transport. Traffic 2: 93–98.
38. Koval M (2006) Claudins: key pieces in the tight junction puzzle. Cell Commun Adhes 13: 127–138.
39. Ruffer G, Gerke V (2004) The C-terminal cytoplasmic tail of claudins 1 and 5 but not its PDZ-binding motif is required for apical localization at epiderhal and endothelial tight junctions. Eur J Cell Biol 83: 135–144.
40. Van Itallie CM, Gambling TM, Carson JL, Anderson JM (2005) Palmitoylation of claudins is required for efficient tight-junction localization. J Cell Sci 118: 1427–1436.
41. Simard A, Di Pietro E, Young CR, Plaza S, Ryan AK (2006) Alterations in heart looping induced by overexpression of the tight junction protein Claudin-1 are dependent on its C-terminal cytoplasmic tail. Mech Dev 123: 219–227.
42. Ivanov AI (2008) Actin motors that drive formation and disassembly of epithelial apical junctions. Front Biosci 13: 6662–6681.
43. Ivanov AI, McCall KG, Parkes CA, Nusrat A (2004) Role for actin filament turnover and a myosin II motor in cytoktoxin-driven disassembly of the epithelial apical junctional complex. Mol Cell Biol 15: 2639–2651.
44. Miyoshi J, Takai Y (2008) Structural and functional associations of apical junctions with cytoskeleton. Biochim Biophys Acta 1778: 670–691.
45. Makrantoniaki E, Zouboulis CC (2007) Molecular mechanisms of skin aging: a multidisciplinary approach. Am J Geriatr Environ Stud 13: 127–138.
46. Ward S (2005) Ehrema and dry skin in older people: identification and management. Br J Community Nurs 10: 453–456.
47. Ghadially R, Brown BE, Sequeira-Martim SM, Feingold KR, Elias PM (1995) The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest 95: 2281–2290.
48. Davies A (2008) Management of dry skin conditions in older people. Br J Community Nurs 13: 250, 252, 254–257.
49. Kluphan LH (1989) Photaging: Manifestations, prevention, and treatment. Clin Geriatr Med 5: 235–251.
50. Barland CO, Zettersten E, Brown BS, Ye J, Elias PM, et al. (2004) Erythromycin-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged mouse epidermis. J Invest Dermatol 122: 330–336.
51. Arabzadeh A, Troy TC, Turksen K (2007) Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorogenesis. BMC Cancer 7: 196.